Natural Investments LLC Raises Holdings in Edwards Lifesciences Corporation $EW

Natural Investments LLC increased its position in Edwards Lifesciences Corporation (NYSE:EW) by 3.2% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,097 shares of the medical research company’s stock after acquiring an additional 156 shares during the period. Natural Investments LLC’s holdings in Edwards Lifesciences were worth $398,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of the company. Arlington Trust Co LLC grew its holdings in shares of Edwards Lifesciences by 1.2% in the 1st quarter. Arlington Trust Co LLC now owns 11,092 shares of the medical research company’s stock worth $804,000 after acquiring an additional 135 shares during the period. Valeo Financial Advisors LLC grew its holdings in shares of Edwards Lifesciences by 2.8% in the 1st quarter. Valeo Financial Advisors LLC now owns 5,136 shares of the medical research company’s stock worth $372,000 after acquiring an additional 142 shares during the period. Allspring Global Investments Holdings LLC grew its holdings in shares of Edwards Lifesciences by 0.5% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 30,195 shares of the medical research company’s stock worth $2,170,000 after acquiring an additional 145 shares during the period. Dakota Wealth Management grew its holdings in shares of Edwards Lifesciences by 2.5% in the 2nd quarter. Dakota Wealth Management now owns 6,048 shares of the medical research company’s stock worth $473,000 after acquiring an additional 146 shares during the period. Finally, Leo Wealth LLC grew its holdings in shares of Edwards Lifesciences by 1.2% in the 1st quarter. Leo Wealth LLC now owns 12,488 shares of the medical research company’s stock worth $905,000 after acquiring an additional 150 shares during the period. Institutional investors and hedge funds own 79.46% of the company’s stock.

Edwards Lifesciences Price Performance

EW stock opened at $74.02 on Friday. Edwards Lifesciences Corporation has a 52-week low of $64.89 and a 52-week high of $83.00. The stock’s fifty day simple moving average is $78.09 and its 200-day simple moving average is $76.13. The company has a quick ratio of 3.87, a current ratio of 4.68 and a debt-to-equity ratio of 0.06. The stock has a market capitalization of $43.46 billion, a price-to-earnings ratio of 10.65, a price-to-earnings-growth ratio of 3.55 and a beta of 1.05.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Thursday, July 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.62 by $0.05. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The business had revenue of $1.53 billion for the quarter, compared to analysts’ expectations of $1.49 billion. During the same quarter last year, the firm earned $0.70 earnings per share. The business’s revenue was up 11.9% on a year-over-year basis. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. Equities research analysts expect that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the company. Wall Street Zen cut Edwards Lifesciences from a “strong-buy” rating to a “buy” rating in a report on Monday, September 29th. The Goldman Sachs Group reiterated a “buy” rating on shares of Edwards Lifesciences in a report on Friday, July 25th. Canaccord Genuity Group increased their target price on Edwards Lifesciences from $75.00 to $81.00 and gave the company a “hold” rating in a report on Friday, July 25th. Truist Financial increased their target price on Edwards Lifesciences from $81.00 to $82.00 and gave the company a “hold” rating in a report on Friday, July 25th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Edwards Lifesciences in a report on Wednesday. Three analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Edwards Lifesciences has an average rating of “Moderate Buy” and a consensus price target of $87.06.

Insider Buying and Selling at Edwards Lifesciences

In other news, insider Larry L. Wood sold 8,950 shares of the firm’s stock in a transaction on Monday, August 18th. The stock was sold at an average price of $78.06, for a total transaction of $698,637.00. Following the sale, the insider owned 206,900 shares in the company, valued at $16,150,614. This trade represents a 4.15% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, VP Daniel J. Lippis sold 4,114 shares of the firm’s stock in a transaction on Monday, July 28th. The stock was sold at an average price of $79.46, for a total value of $326,898.44. Following the sale, the vice president owned 22,002 shares in the company, valued at $1,748,278.92. This trade represents a 15.75% decrease in their position. The disclosure for this sale can be found here. 1.29% of the stock is owned by company insiders.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.